Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7

Cancer Gene Therapy

Volumn 6, Issue 1, 1999, Pages 14-20

  Barnett, Faith H ^a,b,c   Rainov, Nikolai G ^b,d   Ikeda, Keiro ^b   Schuback, Deborah E ^b   Elliott, Peter ^e   Kramm, Christof M ^f   Chase, Maureen ^b   Qureshi, Nazer H ^b   Harsh IV, Griffith ^b   Chiocca, E Antonio ^b   Breakefield, Xandra O ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SCRIPPS CLINIC   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e ALKERMES INC   (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Blood brain barrier; Blood tumor barrier; Carotid artery; Gene therapy; Herpes simplex virus type I; Intra arterial application

Indexed keywords

BRADYKININ; CHROMOGENIC SUBSTRATE; DRUG DERIVATIVE; LOBRADIMIL;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; RAT; TIME;

ANIMALS; BLOOD-BRAIN BARRIER; BRADYKININ; BRAIN NEOPLASMS; CHROMOGENIC COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RATS; TIME FACTORS;

EID: 0032609665     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700003     Document Type: Article

References (37)

1. Loeffler JS, Alexander E, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992;10:1379-1385.
2. Muldoon LL, Kroll RA, Pagel MA, Roman-Goldstein S, Neuwelt EA. Delivery of therapeutic genes to brain and intracerebral tumors. In: Chiocca EA, Breakefield XO, eds. Gene Therapy for Neurological Disorders and Brain Tumors. Boston: Humana Press; 1997;128-139.
3. Kramm CM, Sena-Esteves M, Barnett F, et al. Gene therapy for brain tumors. Brain Pathol. 1995;5:345-381.
4. Ezzeddine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991;3:1-7.
5. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res. 1986;56: 5276-5281.
6. Culver KW, Ram Z, Walbridge S, Hirouki K, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
7. Boviatsis EJ, Parks S, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54: 5745-5751.
8. Takamiya Y, Short MP, Moolten FL, et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg. 1993;79:104-110.
9. Freeman SM, Abboud C, Whartenby K, et al. The "by-stander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
10. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retrovirus vectors. J Natl Cancer Inst. 1990;82:297-300.
11. Bi WL, Parysek LM, Warrick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
12. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol. 1995;13:399-415.
13. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
14. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA. 1994;91: 8185-8189.
15. Kramm CM, Rainov NG, Sena-Esteves M, et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther. 1996;7:1989-1994.
16. Long, DM. Capillary ultrastructure in human metastatic brain tumors. J Neurosurg. 1979;51:53-58.
17. Nilaver G, Muldoon U, Kroll RA, et al. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA. 1995;92:9829-9833.
18. Neuwelt EA, Barnett PA, McCormick CL, Frenkel EP, Minna JD. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery. 1985;17: 419-423.
19. Tomiwa K, Hazama F, Mikawa H. Neurotoxicity of vincristine after osmotic opening of the blood-brain barrier. Neuropathol Appl Neurobiol. 1983;9:345-354.
20. Black KL, Chio CC. Increased opening of blood-tumor barrier by leukotriene C4 is dependent on size of molecules. Neural Res. 1992;14:402-404.
21. Chio CC, Baba T, Black KL. Selective blood-tumor barrier disruption by leukotrienes. J Neurosurg. 1992;77:407-410.
22. Inamura T, Nomura T, Ikezaki K, Fukui M, Pollinger G, Black K. Intracarotid histamine infusion increases blood tumor permeability in RG2 glioma. Neurol Res. 1994;16: 125-128.
23. Black KL. Biochemical opening of the blood-brain barrier. Adv Drug Rev. 1995;15:37-52.
24. Rainov NG, Zimmer C, Chase M, et al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther. 1995;6:1543-1552.
25. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. 1994b; 81:752-758.
26. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol. 1996;141:214-224.
27. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black K. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery. 1996;1:125-134.
28. Black KL, Cloughesy T, Huang SC, et al. Intracarotid infusion of RFM-7, a bradykinin analog and transport of gallium-68 ethylenediamine tetra-acetic acid into human gliomas. J Neurosurg. 1997;86:603-609.
29. Chang S, Barker F, Huhn S, et al. A pilot study of RMP-7 and carboplatin (BDCA) in patients with recurrent malignant glioma. Proc Am Soc Clin Oncol Annu Meet. 1995;14: A305.
30. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol. 1988;62:196-205.
31. Roizman B, Spear PG. Preparation of herpes simplex virus of high titer. J Virol 1968;2:83-84.
32. Rosenberg WS, Breakefield XO, DeAntonio C, Isacson O. Authentic and artifactual detection of the E. coli lacZ gene product in the rat brain by histochemical methods. Brain Res Mol Brain Res. 1992;16:311-315.
33. Turner DL, Snyder EY, Cepko CL. Lineage-independent determination of cell type in the embryonic mouse retina. Neuron. 1990;4:833-845.
34. Conner JM, Muir D, Varon S, Hagg T, Manthorpe, M. The localization of nerve-growth factor-like immunoreactivity in the adult rat basal forebrain and hippocampal formation. J Comp Neurol. 1992;319:454-462.
35. Inamura T, Black K. Bradykinin selectively opens blood tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab. 1994;14:862-870.
36. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58-65.
37. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 1995;55:5451-5458.